(IT-NEWSWIRE.COM, November 08, 2019 ) The growth of Cell Surface Markers market is driven by factors such as the high global prevalence of cancer, growth in stem cell and neurobiology research, and the increasing funding for life sciences research.
Market Size The global Cell Surface Markers Market is projected to reach USD 769 million by 2023 from USD 520 million in 2018, at a CAGR of 8.1% during the forecast period.
“Clinical Applications Segment is Expected to Grow at the Highest CAGR During the Forecast Period” Based on application, the cell surface markers market is segmented into research applications and clinical applications. The clinical applications segment is expected to witness higher growth during the forecast period primarily due to the rising prevalence of cancer and the increasing adoption of cell surface markers in cancer treatment.
“Hospitals & Clinical Testing Laboratories use Cell Surface Markers for the Diagnosis of Various Diseases” On the basis of end user, the cell surface markers market is segmented into academic & research institutes, hospitals & clinical testing laboratories, and pharmaceutical & biotechnology companies. The hospitals & clinical testing laboratories segment is expected to register the highest CAGR during the forecast period. The increasing incidence of chronic diseases such as cancer and HIV is expected to boost the demand for cell surface markers in hospitals & clinical testing laboratories in the coming years.
Recent Developments • In 2018, Thermo Fisher Scientific acquired the Advanced Bioprocessing business of Becton, Dickinson and Company. This will be integrated into the Life Sciences Solutions segment of Thermo Fisher. • In 2018, Abcam entered into an exclusive license agreement with Roche. Under this agreement, the product portfolio of Spring Bioscience Corporation has been licensed to Abcam for research use only (RUO) applications.